Stem cell therapeutics company, Cynata Therapeutics (ASX:CYP), has had another of its studies published in a leading peer-reviewed journal.
It’s asthma study, in a preclinical mouse model, was published in the FASEB Journal – one of the most well-respected and ranked biology journals worldwide. This is the second asthma study result from Cynata that has been published in the FASEB.
The asthma study was conducted under the supervision of Associate Professor Chrishan Samuel and Dr Simon Royce of the Monash Lung Biology Network.
The study showed that Cynata’s stem cells demonstrated efficacy in combination with, or in comparison to, the corticosteroid dexamethasone – the current most common and effective medication for controlling asthma when used regularly.
Cynata’s stem cells are mesenchymal stem cells (MSCs) that are manufactured using its unique proprietary Cymerus™ platform. Importantly, the platform enables manufacture of an infinite amount of MSCs at scale without losing potency or requiring additional donations.
The asthma study showed that treatment with Cynata’s stem cells significantly reduced airway hyperresponsiveness, airway remodelling, and fibrosis compared to corticosteroid treatment and when administered in combination with corticosteroids there was an even better -synergistic- effect.
The combination of MSCs and corticosteroids produced marked anti-inflammatory effects in addition to the benefits seen with Cymerus MSC treatment alone.
“The combination of Cymerus MSCs and dexamethasone resulted in maximal improvement for each endpoint measured. Hence, it can be concluded that such a combination therapy has the potential to improve treatment outcomes in asthmatic patients,” said Monash Lung Biology Network Associate Professor Chrishan Samuel.
Cynata’s Vice President, Product Development, Dr Kilian Kelly, also echoed these sentiments. “These findings further strengthen the body of evidence supporting the use of Cymerus MSCs as a potential asthma treatment,” he said.
“Overall, the results suggest that Cymerus MSCs could be used as a standalone treatment, for example in patients who are unable to tolerate corticosteroids, or as an add-on therapy in patients who are unable to gain control of their condition with existing medications,” he continued.
Asthma impacts over 339 million people globally, creating a potentially very large market for the treatment.
“This is the latest in a series of important studies describing the efficacy of Cymerus MSCs in preclinical models of various diseases, and its publication in a leading peer-reviewed journal provides further independent validation of the promise that the Cymerus platform holds,” said Kelly.
“It broadens the solid evidence supporting the therapeutic utility of Cynata’s Cymerus technology in lung disease and adds to the clinical data from our recently completed Phase 1 trial in graft-versus-host disease (GvHD).”
Cynata has had multiple studies published in peer-review journals including its pre-clinical GvHD trial results and its pre-clinical study of critical limb ischemia (CLI), thereby increasing the global visibility of Cynata’s unique technology and helping to build a sound biology base to support further commercial applications.
Cynata’s stem cells are being investigated as potential treatments for a broad range of indications including three phase two clinical trials that are expected to begin this year in osteoarthritis, GvHD and CLI.
This content is produced by Star Investing in commercial partnership with Cynata Therapeutics. This content does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.
Don’t miss a thing, subscribe now